Literature DB >> 25868386

Poly-autoimmunity in patients with myasthenia gravis: A single-center experience.

Amelia Evoli1, Pietro Caliandro, Raffaele Iorio, Paolo E Alboini, Valentina Damato, Giuseppe LaTorre, Carlo Provenzano, Mirella Marino, Libero Lauriola, Flavia Scuderi, Emanuela Bartoccioni.   

Abstract

We evaluated the co-occurrence of autoimmune diseases (ADs) in a large population of myasthenia gravis (MG) patients from a single center. Our survey included 984 patients, 904 with anti-acetylcholine receptor antibodies and 80 with anti-muscle specific kinase antibodies. The anti-acetylcholine receptor positive population included patients with early-onset (age at onset ≤ 50 years), late-onset and thymoma-associated disease. Follow-up ranged 2-40 years. Two-hundred and fourteen ADs were diagnosed in 185 patients; 26 of them had two or more ADs in association with MG. Thyroid disorders were the most common and, together with vitiligo and thrombocytopenia, occurred in all disease subsets. Otherwise, there was a broad variability with partial overlap among patient groups. The highest rate of ADs was observed in early-onset patients, while clusters, i.e. 2 or more ADs other than MG in the same individual, were more common among thymoma cases. Thirty-four diseases were diagnosed at the same time, 88 occurred before and 92 after the onset of MG. On multivariate analysis, immunosuppressive treatment was the only independent variable which negatively influenced the risk of developing other ADs in our cohort.

Entities:  

Keywords:  Autoimmune diseases; immunosuppressive therapy; myasthenia gravis; thymectomy; thymoma

Mesh:

Substances:

Year:  2015        PMID: 25868386     DOI: 10.3109/08916934.2015.1031890

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  6 in total

1.  Thymomatous myasthenia gravis: novel association with HLA DQB1*05:01 and strengthened evidence of high clinical and serological severity.

Authors:  Roberto Massa; Giulia Greco; Manuela Testi; Emanuele Rastelli; Chiara Terracciano; Erica Frezza; Matteo Garibaldi; Girolama A Marfia; Franco Locatelli; Nicola B Mercuri; Eugenio Pompeo; Giovanni Antonini; Marco Andreani
Journal:  J Neurol       Date:  2019-02-11       Impact factor: 4.849

2.  A 7-year-old boy with dysphagia and proximal muscle weakness.

Authors:  Sivagamy Sithambaram; Neeta Tripathi; Jaya Sujatha Gopal-Kothandapani; Santosh Mordekar
Journal:  Paediatr Child Health       Date:  2017-06-08       Impact factor: 2.253

3.  Juvenile myasthenia gravis in Norway: HLA-DRB1*04:04 is positively associated with prepubertal onset.

Authors:  T H Popperud; M K Viken; E Kerty; B A Lie
Journal:  PLoS One       Date:  2017-10-16       Impact factor: 3.240

Review 4.  Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.

Authors:  Inga Koneczny; Ruth Herbst
Journal:  Cells       Date:  2019-07-02       Impact factor: 6.600

Review 5.  Controversies in Ocular Myasthenia Gravis.

Authors:  Amelia Evoli; Raffaele Iorio
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

6.  Autoimmune vitiligo in rheumatic disease in the mestizo Mexican population.

Authors:  Esperanza Avalos-Díaz; Elena Pérez-Pérez; Mayra Rodríguez-Rodríguez; María-Guadalupe Pacheco-Tovar; Rafael Herrera-Esparza
Journal:  Biomed Rep       Date:  2016-06-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.